T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test powerful new drug cocktail to fight Fast-Growing lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, fast-growing B-cell lymphomas. The goal is to see if this combination is tolerable for patients and to gather initial data on its eff…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat lymphomas: trial tests powerful drug combo
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called epcoritamab to a standard chemotherapy regimen (EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their s…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study is testing whether combining two powerful cancer treatments—CAR-T cell therapy and the drug pembrolizumab—works better than either alone for a type of lymphoma that has returned or not responded to prior treatments. About 35 adults with relapsed or refractory primary m…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC